{
  "docId": "019de070-3a76-76eb-bdcd-70a194f2629a",
  "docSlug": "3b5651eafaa236908b5aaeea5fdc2dcc",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a structured table format to define the clinical problem space.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3a76-76eb-bdcd-70a194f2629a/18",
  "deckHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a",
  "deckJsonHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a.json",
  "deckAnchorHref": "/decks/019de070-3a76-76eb-bdcd-70a194f2629a#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.048,
        "y": 0.13
      },
      "kind": "subtitle",
      "text": "Novel homocysteine/homocystine metabolizing enzyme",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f55ced83-0839-4690-a45f-bc7bab70fa5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.94,
        "x": 0.028,
        "y": 0.25
      },
      "kind": "table",
      "text": "Unmet Medical Need: Very high - no effective therapy for many patients. Early mortality and serious complications: Lens dislocation, glaucoma, severe short-sightedness, skeletal abnormalities, learning problems, vascular abnormalities. Patient Population: >5,000 patients with B6 non-responsive CBS Deficiency. Additional opportunity in B6 responsive patients (>5,000). Diagnosis: Plasma total homocysteine level/enzyme activity assay and/or mutation analysis. Newborn screening in all U.S. states.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6853fd0d-c6e9-454c-af00-df8d7418a410",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.43,
        "x": 0.048,
        "y": 0.07
      },
      "kind": "title",
      "text": "ACN00177: Homocystinuria",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "299846d2-6518-42bc-89f5-52cc4b9cf556",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}